Scient'x USA Announces Appointment of Federico P. Girardi, M.D. to Scientific Advisory Board
BY EDITOR, JUNE 25, 2007
MAITLAND, Fla., June 25 /PRNewswire/ -- Scient'x USA, manufacturer of innovative spinal implant technologies, today announced that Federico P. Girardi, M.D. will be joining their Scientific Advisory Board. Dr. Federico Girardi is an Assistant Attending Orthopaedic Spine Surgeon at the Hospital for Special Surgery in New York City, and also serves as an Assistant Professor of Orthopedics at the Weil Medical College of Cornell University.
"Dr. Girardi is among the nation's foremost thought leaders in Motion Preservation and we are honored he has accepted our invitation to join the Scientific Advisory Board," said Timothy Seese. President and Chief Operations Officer for Scient'x USA. "His experience and knowledge of the spinal industry will be a valuable asset in shaping the development of our Company and our new product programs."
Federico P. Girardi, M.D. completed his medical education at the Universidad Nacional de Rosario in Rosario, Argentina and has done extensive clinical research involving the areas of minimally invasive surgery, clinical outcomes of different surgical procedures, and imaging modalities of the spine. He is also interested in the basic science aspects of bone, disc and nerve tissue regeneration as well as the investigation of alternatives to spinal fusion for the treatment of degenerative disc disease.
Federico P. Girardi, M.D. will serve along with Antonio E. Castellvi, M.D. Peter Klara, M.D., and Robert Peroutka, M.D. on the Scient'x USA Scientific Advisory Board.
Scient'x USA Inc. is a diversified spinal company that designs, manufactures, markets and distributes a comprehensive and innovative range of quality spinal devices. Based in Orlando, Florida, Scient'x USA offers a range of products to treat conditions such as lumbar instability, trauma, and degenerative disc disease. Scient'x USA has become known for producing and marketing the "Isobar TTL Dynamic Spine Stabilization System" and continues to develop new products in conjunction with surgeon physicians for the Orthopaedic and Neurological community. For more information visit http://www.scientxusa.com/.
Except for the historical information contained herein, the matters discussed are forward looking statements made pursuant to the safe harbor provisions of the private securities litigation form act of 1995. These statements involved risks and uncertainties, such as regulatory approvals, manufacturing uncertainties, the impacts of competitive products and pricing, and other risks and uncertainties set forth.
